<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01550432</url>
  </required_header>
  <id_info>
    <org_study_id>SU-03252010-5442</org_study_id>
    <secondary_id>R21AT004475</secondary_id>
    <nct_id>NCT01550432</nct_id>
  </id_info>
  <brief_title>Effects of Glutathione (an Antioxidant) and N-Acetylcysteine on Inflammation</brief_title>
  <official_title>Effects of GSH and N-Acetylcysteine on Inflammatory Markers Among Adults With CVD Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rationale for the potential role of antioxidants in the prevention of cardiovascular&#xD;
      diseases (CVD) remains strong despite the disappointing results of recent trials with a few&#xD;
      select antioxidant vitamins. Glutathione (GSH) is one of the body's most powerful antioxidant&#xD;
      agents but there is a surprising paucity of data on its use as an interventional therapy.&#xD;
&#xD;
      Glutathione, when taken orally, is immediately broken down into its constituent amino acids,&#xD;
      of which cysteine is the only one to be essential. Available cysteine is the critical&#xD;
      determinant of intracellular GSH concentrations. N-acetyl cysteine (NAC) is an antioxidant&#xD;
      supplement that has been used to provide a source of cysteine to replete GSH levels. By&#xD;
      replenishing endogenous glutathione, it is possible that NAC would exert the same effect(s)&#xD;
      as exogenous GSH.&#xD;
&#xD;
      However, there is a new delivery system, liposomal GSH, which keeps glutathione intact. In&#xD;
      this study, the investigators propose to match the cysteine content of NAC and GSH and&#xD;
      compare the effects of these two supplements, at two different doses, on markers of&#xD;
      inflammation and oxidative stress.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory Markers</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxidized LDL</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Sensitivity</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum lipids</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Glutathione levels</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Obesity</condition>
  <condition>Hyperlipidemia</condition>
  <condition>Insulin Resistance</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>High-Dose Glutathione</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2,260 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-Dose Glutathione</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1,130 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-Dose N-Acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1,200 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-Dose N-Acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Volume of liquid placebo product comparable to glutathione and 1 or 2 placebo pills/day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glutathione</intervention_name>
    <description>1,130 mg/day or 2,260 mg/day for 8 weeks</description>
    <arm_group_label>High-Dose Glutathione</arm_group_label>
    <arm_group_label>Low-Dose Glutathione</arm_group_label>
    <other_name>ReadiSorb</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>N-Acetylcysteine</intervention_name>
    <description>600 mg/day or 1,200 mg/day for 8 weeks</description>
    <arm_group_label>High-Dose N-Acetylcysteine</arm_group_label>
    <arm_group_label>Low-Dose N-Acetylcysteine</arm_group_label>
    <other_name>Twinlab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Volume of liquid placebo product comparable to liposomal glutathione and 1 or 2 placebo pills/day.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Nutrilite</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Gender: Both women and men&#xD;
&#xD;
          2. Age: &gt; or = 18 years&#xD;
&#xD;
          3. Ethnicity and race: All ethnic and racial backgrounds welcome&#xD;
&#xD;
          4. Presence of Metabolic Syndrome: As defined in ATP III of the National 5.Cholesterol&#xD;
             Education program, the metabolic syndrome will be diagnosed as presence of at least&#xD;
             three of the following, which will be measured at the screening clinic visit:&#xD;
&#xD;
               -  Central obesity as measured by waist circumference:&#xD;
&#xD;
                    -  Men: Greater than 40 inches&#xD;
&#xD;
                    -  Women: Greater than 35 inches&#xD;
&#xD;
               -  Fasting blood triglycerides greater than or equal to 150 mg/dL&#xD;
&#xD;
               -  Blood HDL cholesterol:&#xD;
&#xD;
                    -  Men: Less than 40 mg/dL&#xD;
&#xD;
                    -  Women: Less than 50 mg/dL&#xD;
&#xD;
               -  Blood pressure greater than or equal to 130/85 mmHg&#xD;
&#xD;
               -  Fasting glucose greater than or equal to 100 mg/dL&#xD;
&#xD;
        6.Planning to be available for clinic visits and bottle pick-ups for the 8 weeks of study&#xD;
        participation 7.Ability and willingness to give written informed consent 8.No known active&#xD;
        psychiatric illness.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Daily intake of dietary supplements containing antioxidants or omega-3 FAs&#xD;
&#xD;
          2. Fasting blood glucose &gt; 140 mg/dL&#xD;
&#xD;
          3. Significant liver enzyme abnormality&#xD;
&#xD;
               -  AST or ALT more than 2 times the upper limit of normal and/or&#xD;
&#xD;
               -  Bilirubin more than 50% the upper limit of normal&#xD;
&#xD;
               -  Renal disease as measured at baseline:&#xD;
&#xD;
               -  Serum creatinine &gt; 1.30 mg/dL, or&#xD;
&#xD;
               -  Calculated creatinine clearance &lt; 71 mL/min&#xD;
&#xD;
          4. Self reported personal history of:&#xD;
&#xD;
               -  Clotting disorders&#xD;
&#xD;
               -  Clinically significant atherosclerosis (e.g., CAD, PAD)&#xD;
&#xD;
               -  Malignant neoplasm&#xD;
&#xD;
               -  Ongoing infection&#xD;
&#xD;
               -  Inflammatory disease (e.g., rheumatoid arthritis)&#xD;
&#xD;
          5. Subjects currently receiving the following medications (self report):&#xD;
&#xD;
               -  Anti-Inflammatory drugs&#xD;
&#xD;
               -  Lipid lowering drugs including statins&#xD;
&#xD;
               -  Anti-hypertensive drugs&#xD;
&#xD;
               -  Anti-coagulant drugs&#xD;
&#xD;
          6. Body Mass Index (BMI) greater than or equal to 40.&#xD;
&#xD;
          7. Pregnant or Lactating&#xD;
&#xD;
          8. Inability to communicate effectively with study personnel&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher D Gardner</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>June 27, 2011</study_first_submitted>
  <study_first_submitted_qc>March 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2012</study_first_posted>
  <last_update_submitted>May 24, 2017</last_update_submitted>
  <last_update_submitted_qc>May 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Christopher Gardner</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

